September 18th 2025
In children aged 10 to <18 with T2D inadequately controlled on standard of care treatment, tirzepatide reduced HbA1c by an average of 2.2% and reduced BMI as well.
September 16th 2025
BREAKING NEWS: FDA Advisers Recommend Diabetes Drug Stay on Market
July 30th 2007Gaithersburg, Md. -- By a vote of 20 to three a group of FDA advisers found evidence that rosiglitazone (Avandia), the popular oral anti-diabetes drug, increases the risk of myocardial infarction. But the same advisers said the drug should stay on the market.